Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Operating Expenses (2016 - 2025)

Historic Operating Expenses for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to $87.7 million.

  • ImmunityBio's Operating Expenses rose 154.24% to $87.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $343.3 million, marking a year-over-year decrease of 658.61%. This contributed to the annual value of $358.9 million for FY2024, which is 108.72% down from last year.
  • Per ImmunityBio's latest filing, its Operating Expenses stood at $87.7 million for Q3 2025, which was up 154.24% from $97.7 million recorded in Q2 2025.
  • ImmunityBio's Operating Expenses' 5-year high stood at $111.9 million during Q1 2023, with a 5-year trough of $77.0 million in Q4 2024.
  • Moreover, its 5-year median value for Operating Expenses was $86.2 million (2021), whereas its average is $87.9 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first skyrocketed by 15775.39% in 2021, then plummeted by 1500.48% in 2025.
  • Over the past 5 years, ImmunityBio's Operating Expenses (Quarter) stood at $79.7 million in 2021, then grew by 6.66% to $85.0 million in 2022, then increased by 0.65% to $85.5 million in 2023, then decreased by 10.03% to $77.0 million in 2024, then rose by 13.96% to $87.7 million in 2025.
  • Its last three reported values are $87.7 million in Q3 2025, $97.7 million for Q2 2025, and $80.9 million during Q1 2025.